Google
NRSN — NEUROSENSE THERAPEUTICS LTD (Healthcare >> Biotechnology)
NRSN FAQ
What is NRSN's ROE?
NEUROSENSE THERAPEUTICS LTD reports a Return on Equity (ROE) of 713.14%.
What is NRSN's dividend yield?
NEUROSENSE THERAPEUTICS LTD offers a dividend yield of 0.00%.
What is NRSN's Deepscope Quality Score?
Deepscope rates NRSN's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NRSN?
Deepscope's AI Timing Score for NRSN is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does NRSN belong to?
NEUROSENSE THERAPEUTICS LTD is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.74
Price
-0.00
(-0.51%)
Day Change
|
|
|---|
NRSN, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 91 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.74 |
| PBV / Sector |
-15.42 / 4.79
|
| Earning Per Share | -0.44 |
| PE / Sector |
N/A / 18.05
|
| PEG or PE/Growth / Sector |
N/A / 0.62
|
| Average 1M Daily Value |
0.10 M
GREAT
|
| Average 1W Daily Value |
0.12 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-12 09:43:55 |
| Symbol | NRSN |
| Name | NEUROSENSE THERAPEUTICS LTD |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 36.10 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 24.06 / 9,010.81 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Building B, Herzliya, Israel, 4672562
Phone: 972 9 799 6183
Website: https://www.neurosense-tx.com
Sector: Healthcare >> Biotechnology
Description: NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
